282 related articles for article (PubMed ID: 33780903)
1. Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab.
De Sanctis R; Giordano L; D'Antonio F; Agostinetto E; Marinello A; Guiducci D; Masci G; Losurdo A; Zuradelli M; Torrisi R; Santoro A
Breast; 2021 Jun; 57():80-85. PubMed ID: 33780903
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
3. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
5. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
6. A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.
Lidbrink E; Chmielowska E; Otremba B; Bouhlel A; Lauer S; Liste Hermoso M; Nüesch E; Shing M; Misra V
Breast Cancer Res Treat; 2019 Feb; 174(1):187-196. PubMed ID: 30506110
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
8. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
9. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM; Ewer MS; Viale G; Delaloge S; Ferrero JM; Verrill M; Colomer R; Vieira C; Werner TL; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C;
Ann Oncol; 2018 Mar; 29(3):646-653. PubMed ID: 29253081
[TBL] [Abstract][Full Text] [Related]
11. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
[TBL] [Abstract][Full Text] [Related]
12. Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.
Davis CC; Zelnak A; Eley JW; Goldstein DA; Switchenko JM; McKibbin T
Ann Pharmacother; 2016 Sep; 50(9):712-7. PubMed ID: 27307412
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ; Procter M; Leyland-Jones B; Goldhirsch A; Untch M; Smith I; Gianni L; Baselga J; Bell R; Jackisch C; Cameron D; Dowsett M; Barrios CH; Steger G; Huang CS; Andersson M; Inbar M; Lichinitser M; Láng I; Nitz U; Iwata H; Thomssen C; Lohrisch C; Suter TM; Rüschoff J; Suto T; Greatorex V; Ward C; Straehle C; McFadden E; Dolci MS; Gelber RD;
N Engl J Med; 2005 Oct; 353(16):1659-72. PubMed ID: 16236737
[TBL] [Abstract][Full Text] [Related]
15. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.
Jackisch C; Kim SB; Semiglazov V; Melichar B; Pivot X; Hillenbach C; Stroyakovskiy D; Lum BL; Elliott R; Weber HA; Ismael G
Ann Oncol; 2015 Feb; 26(2):320-5. PubMed ID: 25403587
[TBL] [Abstract][Full Text] [Related]
17. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Banke A; Fosbøl EL; Ewertz M; Videbæk L; Dahl JS; Poulsen MK; Cold S; Jensen MB; Gislason GH; Schou M; Møller JE
JACC Heart Fail; 2019 Mar; 7(3):217-224. PubMed ID: 30819377
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
[TBL] [Abstract][Full Text] [Related]
20. Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer.
Ishihara M; Mukai H; Nagai S; Mukohara T
Int J Clin Oncol; 2009 Oct; 14(5):431-5. PubMed ID: 19856052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]